A detailed history of Stonepine Capital Management, LLC transactions in Exagen Inc. stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 384,600 shares of XGN stock, worth $699,972. This represents 0.49% of its overall portfolio holdings.

Number of Shares
384,600
Previous 669,684 42.57%
Holding current value
$699,972
Previous $1.33 Billion 54.11%
% of portfolio
0.49%
Previous 0.58%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.42 - $2.3 $404,819 - $655,693
-285,084 Reduced 42.57%
384,600 $612 Million
Q4 2023

Feb 13, 2024

SELL
$1.45 - $2.39 $774,020 - $1.28 Million
-533,807 Reduced 44.35%
669,684 $1.33 Billion
Q3 2023

Nov 13, 2023

BUY
$2.24 - $2.93 $2.7 Million - $3.53 Million
1,203,491 New
1,203,491 $2.91 Billion
Q2 2023

Aug 11, 2023

BUY
$2.36 - $3.48 $28,976 - $42,727
12,278 Added 1.18%
1,049,352 $3.04 Million
Q1 2023

May 12, 2023

BUY
$2.23 - $2.9 $408,161 - $530,792
183,032 Added 21.43%
1,037,074 $2.52 Million
Q4 2022

Feb 14, 2023

SELL
$2.1 - $3.4 $863,795 - $1.4 Million
-411,331 Reduced 32.51%
854,042 $2.05 Million
Q3 2022

Nov 10, 2022

BUY
$3.43 - $8.68 $17,101 - $43,278
4,986 Added 0.4%
1,265,373 $3.43 Million
Q2 2022

Aug 12, 2022

BUY
$4.18 - $7.74 $582,470 - $1.08 Million
139,347 Added 12.43%
1,260,387 $7.24 Million
Q1 2022

May 16, 2022

BUY
$7.12 - $11.06 $1.87 Million - $2.9 Million
262,473 Added 30.57%
1,121,040 $9 Million
Q4 2021

Feb 14, 2022

BUY
$8.97 - $14.08 $4.2 Million - $6.59 Million
467,930 Added 119.79%
858,567 $9.99 Million
Q3 2021

Nov 12, 2021

BUY
$10.25 - $15.21 $2.27 Million - $3.36 Million
221,095 Added 130.41%
390,637 $5.31 Million
Q2 2021

Aug 16, 2021

SELL
$12.4 - $17.92 $266,153 - $384,634
-21,464 Reduced 11.24%
169,542 $2.54 Million
Q1 2021

May 14, 2021

BUY
$13.9 - $22.0 $2.65 Million - $4.2 Million
191,006 New
191,006 $3.34 Million

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $29.6M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.